When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending shares up ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...

This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is ...

A mum has opened up about her daughter’s eczema struggles, saying it was heartbreaking to see her baby’s sheets splattered ...